HRMY

Rating neutralAI MemoPost-earnings T+1

Harmony Biosciences

As of 2026-05-08/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Pitolisant GR NDA timing is the clearest near-term franchise-extension milestone • 2026-06-30

Expected move: +7%

Biggest risk

The bear case is that HRMY remains heavily dependent on WAKIX durability while Q1 already showed more pronounced market-access headwinds, higher royalty burden, sharply higher R&D expense from licensing deals, and lower EPS; if lifecycle execution slips or competition/legal outcomes worsen, the market may treat the current pipeline bridge as insufficient [#8-K-2026-05-07].

Invalidation

Break below $24 or thesis failure.

What would change my mind?

The post-earnings bull case is that Harmony preserved its key de-risking signal at T+1: WAKIX still grew 17% year over year, full-year revenue guidance stayed above $1 billion, liquidity remained strong at $870.5 million, and management laid out multiple franchise-extension shots on goal around Pitolisant GR, Pitolisant HD, BP-205, and EPX-100 [#8-K-2026-05-07].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$33

p=45%

Bull target

$40

p=25%

Bear target

$24

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 print confirmed revenue growth and reiterated 2026 guide, but margins and EPS were pressured by licensing costs
The post-earnings bull case is that Harmony preserved its key de-risking signal at T+1: WAKIX still grew 17% year over year, full-year revenue guidance stayed above $1 billion, liquidity remained strong at $870.5 million, and management laid out multiple franchise-extension shots on goal around Pitolisant GR, Pitolisant HD, BP-205, and EPX-100 [#8-K-2026-05-07].
The packet’s median analyst target is $42 versus a May 7 anchor price of $31.42, implying upside if execution holds, but T+1 revision data and target-change evidence were not available in the checked sources, so that gap keeps the valuation view cautious rather than upgraded.

BearKey bullets

Cost of product sold rose to 20.7% of revenue, driven by new royalties tied to the Novitium license agreement, which can pressure margins even if revenue grows [#8-K-2026-05-07].
Key pipeline and lifecycle milestones including Pitolisant GR, BP-205, and later PWS or Phase 3 programs still carry execution and regulatory timing risk.
Management flagged Q1 market-access headwinds that were more pronounced this year, which bears monitoring for gross-to-net and patient persistence impacts.

WatchKey bullets

Pitolisant GR NDA timing is the clearest near-term franchise-extension milestone

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $33 (p=45%)

Bull/Bear spread: +30% / -22%

Vs latest close: Bull +30% · Base +7% · Bear -22%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $33 (p=45%)Bear Target: $24 (p=30%)

Commentary

This remains a cautious post-earnings monitoring memo rather than a fresh bullish turn. Primary-source support improved materially because the May 7, 2026 earnings release and 8-K confirmed growth, guidance, liquidity, and pipeline timing, but analyst revision evidence was unavailable at T+1. Market reaction also looks muted rather than confirming a rerating: the May 7 anchor close was $31.42 and the latest checked price on May 8, 2026 was $31.02, about 1.3% lower. Combined with the deterministic prior still skewing negative, confidence should stay moderate at best.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 print confirmed revenue growth and reiterated 2026 guide, but margins and EPS were pressured by licensing costs

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$33 / p=45% prob

Bear Target (Scenario probability)

$24 / p=30% prob

Price $31 as of 2026-05-27

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +30% · Base +7% · Bear -22%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
Pitolisant GR NDA timing is the clearest near-term franchise-extension milestone
Management said Pitolisant GR remains on track for NDA submission in Q2 2026 with an anticipated PDUFA date in Q1 2027, supporting the case that Harmony is trying to extend the pitolisant franchise beyond the current WAKIX base and into the 2040s through follow-on IP and formulation work [#8-K-2026-05-07].
Prob 70.00% • Move 9.00% • Priced-in 45.00%
EVENT2026-07-15
Mid-2026 BP-205 Phase 1 PK data is the next meaningful pipeline signal beyond WAKIX
Harmony said BP-205 Phase 1 SAD/MAD work is ongoing in Europe, with clinical PK, safety, and tolerability data from the SAD phase expected in mid-2026 and a U.S. IND also planned for mid-2026; that creates a second-half franchise-diversification check, but it remains early-stage and should be treated cautiously [#8-K-2026-05-07].
Prob 60.00% • Move 8.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Q1 print confirmed revenue growth and reiterated 2026 guide, but margins and EPS were pressured by licensing costs
2026-05-07
Harmony reported Q1 2026 WAKIX net revenue of $215.4 million, up 17% year over year, and reiterated 2026 net revenue guidance of $1.0 billion to $1.04 billion, while noting more pronounced Q1 market-access headwinds; net income fell to $32.5 million from $45.6 million as licensing agreements increased royalties and R&D expense [#8-K-2026-05-07].
Prob 85% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Cost of product sold rose to 20.7% of revenue, driven by new royalties tied to the Novitium license agreement, which can pressure margins even if revenue grows [#8-K-2026-05-07].
Key pipeline and lifecycle milestones including Pitolisant GR, BP-205, and later PWS or Phase 3 programs still carry execution and regulatory timing risk.
Management flagged Q1 market-access headwinds that were more pronounced this year, which bears monitoring for gross-to-net and patient persistence impacts.
R&D expense more than doubled year over year because of up-front licensing payments, and further business-development activity could create additional earnings volatility [#8-K-2026-05-07].
Revenue concentration remains high around WAKIX, so any demand, payer, or generic-pressure change can disproportionately affect the thesis.

Peers

Symbol	Summary
ANIP	ANI Pharmaceuticals is a somewhat closer commercial specialty-pharma comparator by size than large-cap biotech names, but its portfolio mix is broader and less tied to a single sleep-wake franchise, so read-through to HRMY is limited.
PHVS	Pharvaris is a similar-cap biotech reference point for pipeline and regulatory optionality, but it is not a direct operating peer because its disease focus and commercial stage differ materially from Harmony’s WAKIX-led model.
PVLA	Palvella is another loose small-cap biopharma comparator for development-risk framing, but it does not provide a direct benchmark for narcolepsy commercialization or pitolisant lifecycle execution.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: HRMY - Harmony Biosciences - RankAlpha